Tweet
The Lancet. Current status of rabies and prospects for elimination
[Source: The Lancet, full page: (LINK). Abstract, edited.]
The Lancet, Early Online Publication, 12 May 2014 / doi:10.1016/S0140-6736(13)62707-5
Copyright ? 2014 Elsevier Ltd All rights reserved.
Current status of rabies and prospects for elimination
Original Text
Prof Anthony R Fooks PhD a b c d, Ashley C Banyard PhD a b, Daniel L Horton PhD a b, Nicholas Johnson PhD a b, Lorraine M McElhinney PhD a b d, Prof Alan C Jackson MD e
Summary
Rabies is one of the most deadly infectious diseases, with a case-fatality rate approaching 100%. The disease is established on all continents apart from Antarctica; most cases are reported in Africa and Asia, with thousands of deaths recorded annually. However, the estimated annual figure of almost 60 000 human rabies fatalities is probably an underestimate. Almost all cases of human rabies result from bites from infected dogs. Therefore, the most cost-effective approach to elimination of the global burden of human rabies is to control canine rabies rather than expansion of the availability of human prophylaxis. Mass vaccination campaigns with parenteral vaccines, and advances in oral vaccines for wildlife, have allowed the elimination of rabies in terrestrial carnivores in several countries worldwide. The subsequent reduction in cases of human rabies in such regions advocates the multidisciplinary One Health approach to rabies control through the mass vaccination of dogs and control of canine populations.
_____
a Animal Health and Veterinary Laboratories Agency (AHVLA, Weybridge), New Haw, Addlestone, UK; b WHO Communicable Disease Surveillance and Response Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, Addlestone, Weybridge, UK; c Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; d National Consortium for Zoonosis Research, University of Liverpool, Leahurst, Neston, UK; e Departments of Internal Medicine (Neurology) and of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
Correspondence to: Prof Anthony R Fooks, Animal Health and Veterinary Laboratories Agency (AHVLA, Weybridge), New Haw, Addlestone, Surrey KT15 3NB, UK
-
-------
The Lancet, Early Online Publication, 12 May 2014 / doi:10.1016/S0140-6736(13)62707-5
Copyright ? 2014 Elsevier Ltd All rights reserved.
Current status of rabies and prospects for elimination
Original Text
Prof Anthony R Fooks PhD a b c d, Ashley C Banyard PhD a b, Daniel L Horton PhD a b, Nicholas Johnson PhD a b, Lorraine M McElhinney PhD a b d, Prof Alan C Jackson MD e
Summary
Rabies is one of the most deadly infectious diseases, with a case-fatality rate approaching 100%. The disease is established on all continents apart from Antarctica; most cases are reported in Africa and Asia, with thousands of deaths recorded annually. However, the estimated annual figure of almost 60 000 human rabies fatalities is probably an underestimate. Almost all cases of human rabies result from bites from infected dogs. Therefore, the most cost-effective approach to elimination of the global burden of human rabies is to control canine rabies rather than expansion of the availability of human prophylaxis. Mass vaccination campaigns with parenteral vaccines, and advances in oral vaccines for wildlife, have allowed the elimination of rabies in terrestrial carnivores in several countries worldwide. The subsequent reduction in cases of human rabies in such regions advocates the multidisciplinary One Health approach to rabies control through the mass vaccination of dogs and control of canine populations.
_____
a Animal Health and Veterinary Laboratories Agency (AHVLA, Weybridge), New Haw, Addlestone, UK; b WHO Communicable Disease Surveillance and Response Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, Addlestone, Weybridge, UK; c Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; d National Consortium for Zoonosis Research, University of Liverpool, Leahurst, Neston, UK; e Departments of Internal Medicine (Neurology) and of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
Correspondence to: Prof Anthony R Fooks, Animal Health and Veterinary Laboratories Agency (AHVLA, Weybridge), New Haw, Addlestone, Surrey KT15 3NB, UK
-
-------